Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000018645
JPRN-UMIN000018645
Completed
未知

A phase II study of antithymocyte globulin in patients undergoing HLA-matched allogeneic peripheral blood stem cell transplantation - JSCT-ATG15

JSCT0 sites77 target enrollmentStarted: October 1, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAML,ALL,HL,NH

Overview

Phase
未知
Status
Completed
Sponsor
JSCT
Enrollment
77
OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

ow-dose ATG as a GVHD prophylaxis showed safety and efficacy for the prevention of both acute and chronic GVHD in HLA-matched PBSCT using myeloablative conditioning.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
15years-old to 60years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\. Patients who are positive for HIV antibody. 2\. Patients with active other malignancies. 3\. Patients with active infectious disease. 4\. Women who are pregnant, of childbearing potential, or lactating. 5\. Patients who experienced serious hypersensitivity or anaphylaxis to antithymocyte globulin. 6\. Patients who has a prior history of allogeneic transplantation. 7\. Patients who are not eligible for this study at the discretion of the investigator.

Investigators

Sponsor
JSCT

Similar Trials

Completed
Phase 4
Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCTaGVHD
NCT02677181Chinese PLA General Hospital100
Completed
Phase 2
Antithymocyte Globulin and Cyclosporine to Treat MyelodysplasiaMyelodysplastic Syndrome
NCT00005937Neal Young, M.D.42
Terminated
Phase 2
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsAcute LeukemiaChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveDiffuse Large B-Cell LymphomaFollicular LymphomaGraft Versus Host DiseaseMantle Cell LymphomaMarginal Zone LymphomaMyelodysplastic SyndromeMyelofibrosisMyeloproliferative NeoplasmSmall Lymphocytic Lymphoma
NCT02877082Emory University5
Completed
Phase 3
Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)Graft vs Host Disease
NCT00655343Neovii Biotech202
Unknown
Phase 2
Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCTaGVHDcGVHD
NCT05214066Chinese PLA General Hospital60